ADMA Biologics Inc  

(Public, NASDAQ:ADMA)   Watch this stock  
Find more results for ADMA
+0.27 (9.31%)
Nov 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.90 - 3.19
52 week 2.01 - 6.10
Open 2.92
Vol / Avg. 0.00/192,822.00
Mkt cap 81.77M
P/E     -
Div/yield     -
EPS -2.00
Shares 25.79M
Beta 1.97
Inst. own 33%
Feb 22, 2018
Q4 2017 ADMA Biologics Inc Earnings Release (Estimated) Add to calendar
Nov 3, 2017
Q3 2017 ADMA Biologics Inc Earnings Release
Sep 11, 2017
ADMA Biologics Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -321.45% -183.05%
Operating margin -305.06% -162.56%
EBITD margin - -158.15%
Return on average assets -77.46% -82.34%
Return on average equity -299.83% -
Employees 92 -
CDP Score - -


C/O Adma Biologics Inc., 465 State Route 17
RAMSEY, NJ 07446
United States - Map
+1-201-4785552 (Phone)
+1-201-4785553 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Officers and directors

Steven A. Elms Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Adam S. Grossman President, Chief Executive Officer, Director
Age: 38
Bio & Compensation  - Reuters
Jerrold B. Grossman D.P.S Vice Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Brian Lenz Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
James Mond M.D., Ph.D. Chief Scientific and Medical Officer
Age: 69
Bio & Compensation  - Reuters
Bernhard R. M. Ehmer Director
Age: 62
Bio & Compensation  - Reuters
Bryant E. Fong Independent Director
Bio & Compensation  - Reuters
Dov A. Goldstein M.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Lawrence P. Guiheen Independent Director
Age: 64
Bio & Compensation  - Reuters
Eric I. Richman Independent Director
Age: 55
Bio & Compensation  - Reuters